Impact of Omega 3 in Treatment of Inappropriate Sinus Tachycardia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07138131

Enrollment

Registered

2025-08-22

Start date

2023-10-01

Completion date

2024-09-01

Last updated

2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inappropriate Sinus Tachycardia, Omega 3, Treatment

Brief summary

This study aimed to evaluate the effect of omega-3 supplementation on heart rate (HR) control and heart rate variability (HRV) in children with inappropriate sinus tachycardia (IST).

Detailed description

Inappropriate sinus tachycardia (IST) is a is a common disease of the autonomic nervous system in children in which tachyarrhythmia characterized by a persistent increase in resting sinus rate or disproportionate elevation of heart rate (HR) with minimal physiological effort accompanied by wide ranging symptoms including palpitations, fatigue, presyncope, and exercise intolerance it could cause lead to total disability in severe cases .it also takes a chronic course with Significant adverse effects on quality of life.

Interventions

DRUGOmega 3

Patients received omega-3 supplementation for 3 months.

OTHERStandard follow-up

Patients received standard follow-up without treatment.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to 16 Years

Healthy volunteers

Inclusion criteria

* Age from 12 to 16 years. * Both sexes. * Patients diagnosed with inappropriate sinus tachycardia (IST). * Patients with resting heart rate (HR) ≥100 bpm (sitting) and/or 24-hour average HR ≥90.

Exclusion criteria

* Structural heart disease. * Patients receiving antiarrhythmic medication. * Patients with a prior history of arrhythmias such as paroxysmal supraventricular tachycardia (PSVT) or sick sinus syndrome, or orthostatic hypotension. * Secondary conditions such as anemia, infection, or hyperthyroidism.

Design outcomes

Primary

Measure	Time frame	Description
Heart rate	24 hours post-treatment	Heart rate was recorded at baseline and post-treatment.

Secondary

Measure	Time frame	Description
Heart rate variability (HRV)	24 hours post-treatment	Heart rate variability (HRV) was recorded at baseline and post-treatment.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026